

# Curriculum Vitae

James D Doecke

Level 5, UQ Health Sciences Building 901/16  
Royal Brisbane and Women's Hospital  
Herston 4006, Australia

Ph (617) 3253 3697

Fax (617) 3253 3690

E-mail: [james.doecke@csiro.au](mailto:james.doecke@csiro.au)

## Educational History and Qualifications

2002 - 2006 PhD, Griffith University (GC)

2002 Bachelor Health Science 1st Class Honours, Griffith University (GC)

## Employment History

2008 - Present Senior Research Scientist/Team leader (Biostatistics)

CSOF 6 CSIRO Digital Productivity Flagship

Australian Imaging Biomarkers and Lifestyle (AIBL)

2006 - 2008 Adjunct Associate Lecturer

Griffith Medical Research College

2006-2008 Biostatistician

Statistical consulting for QIMR/RBWH, statistical research for the Cancer and Population Studies Group.

## Professional Society Memberships

2011 - Current Australian Biometrics Society

2015 - Current Alzheimer's Association

## Awards

2011 CSIRO Julius Career Award

2010 CSIRO Accelerated Advancement Award

2008 Publication in GUT won editors choice

2005 Young Investigator of the Year Award for the Australian and New Zealand Bone and Mineral Society

2002 Golden Key International Honours Award

## Peer review activities

2017 - Current Frontiers in Neurology

2016 - Current Biomarkers in Medicine

2014 - Current Journal of Alzheimer's Disease

2014 - Current PLoS One

2014 - Current Alzheimer's Research and Therapy

## Invited presentations/visits

2017 Invited visit to the **Cambridge Centre for Neuropsychiatric Research**, University of Cambridge UK.

2016 Invited oral presentation CSIRO Computation and Simulation Sciences FOAM conference, Melbourne AU.

2013/4/5/6 Invited visit to the Biostatistics Laboratory at the MD Anderson Cancer Center, Houston USA.

2012 Invited visit to the Cambridge Institute for Medical Research, Cambridge UK.

## Publication metrics

Total Citations: 1936

Total journal publications: 62

in last APA cycle 17

Total conference publications: 51

H-Index: 20

## Mentoring roles

2016/17 CSIRO Summer vacation student

2015/16 CSIRO Summer vacation student

2014-Current PhD Student Marcela Cespedes  
2006-2006 Honours Student Jessica Gale  
School of Medical Science Griffith University (GC)

#### Workshops/Courses attended

2017 CSIRO Leadership essentials program. CSIRO Brisbane, 3 days.  
2017 Understanding the Genetic Architecture of Complex Traits Through SNP-based Heritability Analysis. GeneMappers Conference, 1/2 day.  
2017 CSIRO Launchcamp, CSIRO Melbourne, 2 days.  
2016 Introduction to Bioconductor/shiny workshop. QUT Brisbane, 1 day.  
2015 Nature Journal Masterclass, Brisbane, 2 days.  
2014 Software Carpentry Python bootcamp, UQ Brisbane. 2 days.  
2012 Project Leader Fundamentals. CSIRO in partnership with QVC Solutions. 2 days.  
2012 Introduction to Bayesian Analyses using WinBUGS. Medical Research Council Biostatistics Unit, Cambridge UK. 2 days.  
2011 Publishing with impact. CSIRO. Brisbane Australia. 2 days.  
2011 An overview of modern regression modelling. CSIRO. Brisbane, 3 days.  
2011 Generalized Linear Models and their analysis in GenStat. Australian Applied Statistics Conference. Palm Cove, 1 day.  
2009 Strategies for extracting reliable information from micro array data. International Society for Clinical Biostatistics. Prague, 1 day.  
2007 European Educational Program in Epidemiology: Statistical designs and analyses of genetic epidemiology studies. Florence, 5 days.

#### International collaborations

2008-Current The ANZ Inflammatory Bowel Disease Consortium, 12 sites across Australia and New Zealand.  
2011-Current International Inflammatory Bowel Disease Genetics Consortium (IIBDGC), multiple centre's worldwide.  
2012-2012 JDRF/Wellcome Trust Diabetes and Inflammation Laboratory Cambridge Institute for Medical Research, University of Cambridge, Wellcome Trust/MRC Building, Addenbrooke's Hospital, Cambridge, United Kingdom.  
2013-Current Biostatistics Unit, MD Anderson Cancer Center, Houston Texas, United States of America.  
2014-Current Department of Biostatistics and Computational Biology, Harvard School of Public Health, Boston Massachusetts, United States of America.  
2014-Current Preclinical Work Group on Statistical Methods. Multiple sites across Australia and the United States of America.

#### Research Work in Progress

2017 Current research includes investigations into:  
1. Biomarkers of Alzheimer's Disease within the Australian Imaging Biomarkers and Lifestyle Study,  
2. Statistical genetics of Inflammatory Bowel Disease.  
3. Statistical genetics of Cancer.

## Publications

1. Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY, Diouf I, Farquharson S, Fripp J, Ames D, **Doecke JD**, Desmond P, Ordidge R, Masters CL, Rowe CC, Maruff P, Villemagne VL, Salvado O, Bush AI, for the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. (2017). Quantitative susceptibility mapping as a predictor of amyloid-related cognitive decline. *Brain*. [Accepted an in press].  
Journal Impact Factor: 10.103. Citations: 0
2. Gupta VB, Hone E, Pedrini S, **Doecke JD**, O'Bryant S, James I, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Martins RN, AIBL Research Group. (2017). Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. [Epub ahead of print].  
Journal Impact Factor: TBA. Citations: 0
3. Frost S, Bhuiyan A, Offerman D, **Doecke JD**, Macaulay SL, Sohrabi HR, Ames D, Masters C, Martins RN, Kanagasam Y, Aibl Research Group. (2017). Modulation of Retinal Arteriolar Central Reflection by APOE genotype. *Curr Alzheimer Res*. [Epub ahead of print]  
Journal Impact Factor: 4.953. Citations: 0
4. Roberts BR, Lind M, Wagen AZ, Rembach A, Frugier T, Li QX, Ryan TM, McLean CA, **Doecke JD**, Rowe CC, Villemagne VL, Masters CL. (2017). Biochemically-defined pools of amyloid- $\beta$  in sporadic Alzheimer's disease: correlation with amyloid PET. *Brain*. [Epub ahead of print]  
Journal Impact Factor: 10.103. Citations: 0
5. Radford- Smith GL, Hartnell F, **Doecke JD**. (2017). Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort—authors' reply. *Alimentary Pharmacology & Therapeutics*: 45(6):856-857.  
Journal Impact Factor: 5.727. Citations: 0
6. Cespedes, MI, Fripp J, McGree JM, Drovandi CC, Mengersen K, and **Doecke JD**. (2017). Comparisons of neurodegeneration over time between healthy ageing and Alzheimer's disease cohorts via Bayesian inference. *BMJ Open* 7(2): e012174.  
Journal Impact Factor: 2.271. Citations: 0
7. **Doecke JD**, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, Lewindon P, Jones LV, Sewell K, Krishnaprasad K, Prosser R, Marr D, Fischer J, R Thomas G, Tehan JV, Ding NS, Cooke SE, Moss K, Sechi A, De Cruz P, Grafton R, Connor SJ, Lawrance IC, Gearry RB, Andrews JM, Radford-Smith GL; Australian and New Zealand Inflammatory Bowel Disease Consortium. (2017). Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. *Aliment Pharmacol Ther* 45(4): 542-552.  
Journal Impact Factor: 5.727. Citations: 3
8. Pietrzaka RH, Laws SM, Lim YY, Bender SJ, Porter T, **Doecke JD**, Amesh D, Fowler C, Masters CL, Milicic L, Rainey-Smith S, Villemagne VL, Rowe CC, Martins RN, Maruff P. (2017). Plasma Cortisol, Brain Amyloid- $\beta$ , and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. *Biol. Psychiatry* 2(1):45-52.  
Journal Impact Factor: 11.212. Citations: 0
9. Pagnozzi AM, Dowson N, **Doecke JD**, Fiori S, Bradley AP, Boyd RN, Rose S, (2016). Automated, quantitative measures of grey and white matter lesion burden correlates with motor and cognitive function in children with unilateral cerebral palsy. *NeuroImage: Clinical* 11:751-759.  
Journal Impact Factor: 3.857. Citations: 0
10. Gupta VB, **Doecke JD**, Hone E, Pedrini S, Laws SM, Thambisetty M, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Macaulay SL, Rembach A, Rainey-Smith SR, Martins RN. (2016). Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* 3;18-26

Journal Impact Factor: TBA. Citations: 5

11. Roberts BR, **Doecke JD**, Rembach A, Yévenes LF, Fowler CJ, McLean CA, Lind M, Volitakis I, Masters CL, Bush AI, Hare DJ; AIBL research group. (2016). Rubidium and potassium levels are altered in Alzheimer's disease brain and blood but not in cerebrospinal fluid. *Acta Neuropathol Commun* 14;4(1):119.  
Journal Impact Factor: TBA. Citations: 1

12. Pagnozzi AM, Shen K, **Doecke JD**, Boyd RN, Bradley AP, Rose S, Dowson N. (2016). Using ventricular modeling to robustly probe significant deep gray matter pathologies: Application to cerebral palsy. *Hum Brain Mapp* 37(11):3795-3809.  
Journal Impact Factor: 5.969. Citations: 0

13. **Doecke JD**, Y. Wang and K. Baggerly. (2016). Co-localized genomic regulation of miRNA and mRNA via DNA methylation affects survival in multiple tumor types. *Cancer Genet* 209(10): 463-473.  
Journal Impact Factor: 2.333. Citations: 0

14. Pagnozzi AM, Dowson N, Fiori S3 **Doecke JD**, Bradley AP, Boyd RN, Rose S. (2016). Alterations in regional shape on ipsilateral and contralateral cortex contrast in children with unilateral cerebral palsy and are predictive of multiple outcomes. *Hum Brain Mapp* 37(10): 3588-603.  
Journal Impact Factor: 5.969. Citations: 1

15. Burnham SC, Rowe CC, Baker D, Bush AI, **Doecke JD**, Faux NG, Laws SM, Martins RN, Maruff P, Macaulay SL, Rainey-Smith S, Savage G, Ames D, Masters CL, Wilson W, Villemagne VL. (2016). Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up. *Neurology* 87(11): 1093-1101.  
Journal Impact Factor: 8.286. Citations: 0

16. Chekouo T, Stingo FC, **Doecke JD**, and Do KA. (2016). A Bayesian integrative approach for multi-platform genomic data: A kidney cancer case study. *Biometrics* [Epub ahead of print].  
Journal Impact Factor: 1.827. Citations: 0

17. Gu BJ, Huang X, Ou A, Rembach A, Fowler C, Avula PK, Horton A, **Doecke JD**, Villemagne VL, Macaulay SL, Maruff P, Fletcher EL, Guymer R, Wiley JS, Masters CL; Australian Imaging, Biomarkers and Lifestyle (AIBL) Study. (2016). Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer's disease. *Acta Neuropathol* 132(3): 377-389.  
Journal Impact Factor: 11.360. Citations: 0

18. Hume GE, **Doecke JD**, Huang N, Fowler EV, Brown IS, Simms LA, Radford-Smith GL. (2016). Altered Expression of Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn's Disease. *J Gastrointest Liver Dis* 25(1):39-48.  
Journal Impact Factor: 2.387. Citations: 1

19. Pagnozzi AM, Fiori S, Boyd RN, Guzzetta A, **Doecke JD**, Gal Y, Rose S, Dowson N. (2015). Optimization of MRI-based scoring scales of brain injury severity in children with unilateral cerebral palsy. *Pediatr Radiol* 46(2):270-9.  
Journal Impact Factor: 1.19 Citations: 2

20. Sahama I, Sinclair K, Fiori S, **Doecke JD**, Pannek K, Reid L, Lavin M, Rose S. (2015). Motor pathway degeneration in young ataxia telangiectasia patients: A diffusion tractography study. *Neuroimage Clin* 20;9:206-15.  
Journal Impact Factor: 2.53 Citations: 3

21. Rembach A, Evered LA, Li QX, Nash T, Vidaurre L, Fowler CJ, Pertile KK, Rumble RL, Trounson BO, Maher S, Mooney F, Farrow M, Taddei K, Rainey-Smith S, Laws SM, Macaulay SL, Wilson W, Darby DG, Martins RN, Ames D, Collins S, Silbert B, Masters CL, **Doecke JD**; AIBL Research Group. (2015). Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. *Alzheimers Res Ther* 19;7(1):71.

Journal Impact Factor: 3.5 Citations: 3

22. Cheng L, **Doecke JD**, Sharples R, Villemagne VL, Fowler CJ, Rembach A, Martins RN, Rowe C, Macaulay SL, Masters CL, Hill AF. (2014). Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. *Molecular Psychiatry*: 20(10):1188-1196.

Journal Impact Factor: 15.15 Citations: 50

23. Li QX, Villemagne VL, **Doecke JD**, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group. (2015). Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid- $\beta$  Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. *J Alzheimers Dis* 48(1):175-87.

Journal Impact Factor: 4.15 Citations: 7

24. Chekouo T, Stingo FC, **Doecke JD**, Do KA. (2015). miRNA-target gene regulatory networks: A Bayesian integrative approach to biomarker selection with application to kidney cancer. *Biometrics* 71(2):428-38

Journal Impact Factor: 1.83 Citations: 7

25. **Doecke JD**, Simms LA, Zhao ZZ, Roberts RL, Fowler EV, Croft A, Lin A, Huang N, Whiteman DC, Florin THJ, Barclay ML, Merriman TR, Gearry RB, Montgomery GW, Radford-Smith GL. (2014). Smoking behaviour modifies IL23R-Crohn's Disease risk in patients with Crohn's Disease. *Journal of Gastroenterology and Hepatology* 30(2):299-307.

Journal Impact Factor: 3.63 Citations: 4

26. Hare DJ, **Doecke JD**, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI, Roberts BR. (2015). Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. *ACS Chem Neurosci* 18;6(3):398-402.

Journal Impact Factor: 4.21 Citations: 17

27. Rembach A, Stingo FC, Peterson C, Vannucci M, Do KA, Wilson WJ, Macaulay SL, Ryan TM, Martins RN, Ames D, Masters CL, **Doecke JD** and the AIBL Research Group. (2014). Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's Disease. *Journal of Alzheimer's Disease* 44(3):917-25.

Journal Impact Factor: 4.15 Citations: 1

28. Rembach A, Watt A, Wilson W, Rainey-Smith S, Ellis K, Rowe C, Villemagne V, Bush AI, Martins RN, Ames D, Masters C, **Doecke JD**. (2014). An increased Neutrophil-Lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. *Journal of Alzheimer's Disease* 273(1-2):65-71.

Journal Impact Factor: 4.15 Citations: 14

29. Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, **Doecke JD**, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe CC, Salvado O, Macaulay SL, Masters CL, Villemagne VL; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging, Biomarkers and Lifestyle Study Research Group. (2013). A blood-based predictor for neocortical A $\beta$  burden in Alzheimer's disease: results from the AIBL study. *Mol Psychiatry* 19(4):519-26.

Journal Impact Factor: 15.15 Citations: 47

30. **Doecke JD**, Chekouo TT, Stingo F, Do KA. (2014). miRNA Target Gene Identification: Sourcing miRNA Target Gene Relationships for the Analyses of TCGA Illumina MiSeq and RNA-Seq HiSeq Platform Data. *Int J Hum Genet* 14(1): 17-22.

Journal Impact Factor: 0.16 Citations: 4

31. Rembach A, Hare DJ, **Doecke JD**, Burnham SC, Volitakis I, Fowler CJ, Cherny RA, McLean C, Grimm R, Martins R, Ames D, Masters CL, Bush AI, Roberts BR. (2014). Decreased serum zinc is an effect of ageing and not Alzheimer's disease. *Metallomics* 6(7):1216-9.

Journal Impact Factor: 3.98 Citations: 13

32. Ferreira RC, Guo H, Coulson RM, Smyth DJ, Pekalski ML, Burren OS, Cutler AJ, **Doecke JD**, Flint S, McKinney EF, Lyons PA, Smith KG, Achenbach P, Beyerlein A, Dunger DB, Wicker LS, Todd JA, Bonifacio E, Wallace C, Ziegler AG. (2014). A type I interferon transcriptional signature precedes autoimmunity in children genetically at-risk of type 1 diabetes. *Diabetes* 63(7):2538-50. Journal Impact Factor: 8.47 Citations: 28
33. Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, **Doecke JD**. (2013). Plasma Amyloid- $\beta$  Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. *J Alzheimers Dis* 40(1):95-104. Journal Impact Factor: 4.15 Citations: 20
34. Squitti R, Simonelli I, Ventriglia M, Siotto M, Pasqualetti P, **Doecke JD**, Rembach A, Bush AI. (2013). Meta-analysis of serum Non-ceruloplasmin copper in Alzheimer's disease. *Journal of Alzheimer's Disease* 38(4):809-22. Journal Impact Factor: 4.15 Citations: 42
35. Croft A, Walsh A, Doecke JD, Radford-Smith G. (2013). Letter: ciclosporin or infliximab in acute ulcerative colitis- still undecided; authors' reply. *Alimentary pharmacology & therapeutics* 38(8), 993-993. Journal Impact Factor: 5.48 Citations: 0
36. Croft A, Walsh A, **Doecke JD**, Radford-Smith G. (2013). Commentary: salvage medical therapy for acute severe colitis-ciclosporin or infliximab? author's reply. *Aliment Pharmacol Ther* 38(8):989-989. Journal Impact Factor: 5.48 Citations: 1
37. Rembach A, Ryan TM, Roberts BR, **Doecke JD**, Wilson WJ, Watt AD, Barnham KJ, Masters CL. (2013). Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. *Biomark Med* 7(4):641-62. Journal Impact Factor: 2.86 Citations: 15
38. Croft A, Walsh A, **Doecke JD**, Cooley R, Howlett M, Radford-Smith G. (2013). Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. *Aliment Pharmacol Ther* 38(3):294-302. Journal Impact Factor: 5.48 Citations: 48
39. **Doecke JD**, Simms LA, Zhao ZZ, Huang N, Hanigan K, Krishnaprasad K, Roberts RL, Andrews JM, Mahy G, Bampton P, Lewindon P, Florin T, Lawrance IC, Geary RB, Montgomery GW, Radford-Smith GL. (2013). Genetic susceptibility in IBD: overlap between ulcerative colitis and Crohn's disease. *Inflamm Bowel Dis* 19(2):240-5. Journal Impact Factor: 5.48 Citations: 25
40. Laws SM, **Doecke JD**, Martins RN. (2012). In reply: Blood-based biomarkers in Alzheimer's disease: where are we now, where have we to go? *JAMA Neurol* 70(1):133-4. Journal Impact Factor: 7.01 Citations: 2
41. Rembach A, **Doecke JD**, Roberts BR, Watt AD, Faux NG, Volitakis I, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Wilson W, Ellis KA, Martins RN, Rowe CC, Villemagne VL, Ames D, Masters CL, AIBL research group, Bush AI. (2013). Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. *J Alzheimers Dis* 34(1):171-82. Journal Impact Factor: 4.15 Citations: 24
42. **Doecke JD**, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeki C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; for the Alzheimer's Disease Neuroimaging Initiative and Australian Imaging Biomarker and Lifestyle Research Group. (2012). Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. *Arch Neurol* 16:1-8.

Journal Impact Factor: 7.01 Citations: 188

43. Morrison NA, Stephens AA, Osato M, Polly P, Tan TC, Yamashita N, **Doecke JD**, Fozzard N, Jones G, Ralston SH, Sambrook PN, Prince RL, Nicholson GC. (2012). Glutamine repeat variants in human RUNX2 associated with decreased femoral neck BMD, calcaneal broadband ultrasound and target gene transactivation. PLoS One 7(8):e42617.

Journal Impact Factor: 3.53 Citations: 9

44. Krishnaprasad K, Andrews J, Grafton R, Lawrance I, Florin T, Leong R, Mahy G, Cooke S, Croft A, Prosser R, Leach P, Edwards S, Chitti L, Cock C, Bampton P, Gearry R, **Doecke JD**, Radford-Smith G. (2011). Inter-Observer Agreement for Crohn's Disease Sub-Phenotypes using the Montreal Classification: How good are we? A Multi-Centre Australasian Study. Journal of Crohn's and Colitis 6(3):287-93.

Journal Impact Factor: 3.56 Citations: 16

45. Herath N, Spanevello M, **Doecke JD**, Smith F, Pouponnot C, Boyd A. (2011). Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. European Journal of Cancer 48 (5), 753-762.

Journal Impact Factor: 4.82 Citations: 30

46. Hume GE, Fowler EV, Griffiths LR, **Doecke JD**, Radford-Smith GL. (2012). Common PPAR $\gamma$  variants C161T and Pro12Ala are not associated with Inflammatory Bowel Disease in an Australian cohort. Journal of Gastrointestinal and Liver Diseases 21(4):349-55.

Journal Impact Factor: 1.85 Citations: 1

47. Gray P, Kirby J, Smith MT, Cabot PJ, Williams B, **Doecke JD**, Cramond T. (2011). Pregabalin in severe burn injury pain: A double-blind, randomised placebo-controlled trial. Pain 152 (6), 1279-1288.

Journal Impact Factor: 5.84 Citations: 33

48. Biesiekierski J, Newnham E, Irving P, Barrett J, Haines M, **Doecke JD**, Shepherd S, Muir J, Gibson P. (2011). Gluten causes gastrointestinal symptoms in subjects without Coeliac Disease: A double blind, randomised placebo controlled trial. American Journal of Gastroenterology 106(3):508-14.

Journal Impact Factor: 9.21 Citations: 567

49. Simms, L.A, **Doecke JD**, Roberts, R.L, Fowler, E.V, Zhao, Z.Z, McGuckin, M.A, Huang, N, Hayward, N.K, Webb, P.M, Whiteman, D.C, Cavanaugh, J.A, McCallum, R, Florin, T.H.J, Barclay, M.L, Gearry, R.R, Merriman, T.R, Montgomery, G.W, Radford-Smith, G.L. (2010). KCNN4 gene variant is associated with ileal Crohn's disease in the Australian and New Zealand Population. American Journal of Gastroenterology. 105(10) 2209-17.

Journal Impact Factor: 9.21 Citations: 49

50. Beesley VL, Clavarino AM, Webb PM, Wyld DK, Francesconi AB, Horwood KR, **Doecke JD**, Loos CA, Green AC. (2010). Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Supportive Care in Cancer 18(8):943-949.

Journal Impact Factor: 2.5 Citations: 2

51. Herath NI, **Doecke JD**, Spanevello MD, Leggett BA, Boyd AW. (2009). Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. British Journal of Cancer 100(7)1095-1102.

Journal Impact Factor: 4.82 Citations: 56

52. Simms, LA; Doecke, JD; Radford-Smith, GL. (2009). Decreased Paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007fs genotype Reply. GUT 58(6)883-884.

Journal Impact Factor: 13.32 Citations: 1

53. Neale RE, **Doecke JD**, Pandeya N, Sadhegi S, Green AC, Webb PM, Whiteman DC. (2009). Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? *British Journal of Cancer* 100(5)795-798.  
Journal Impact Factor: 2.64 Citations: 38
54. Ramm GA, Shepherd RW, Hoskins AC, Greco SA, Ney AD, Pereira TN, Bridle KR, **Doecke JD**, Meikle PJ, Turlin B, Lewindon PJ. (2009). Fibrogenesis in Pediatric Cholestatic Liver Disease: Role of Taurocholate and Hepatocyte-Derived Monocyte Chemotaxis Protein-1 in Hepatic Stellate Cell Recruitment. *Hepatology* 49(2)533-544.  
Journal Impact Factor: 11.19 Citations: 82
55. Fowler EV, **Doecke JD**, Simms LA, Zhao ZZ, Webb PM, Hayward NK, Whiteman DC, Florin TH, Montgomery GW, Cavanaugh JA, Radford-Smith GL. (2008). ATG16L1 T300A Shows Strong Associations With Disease Subgroups in a Large Australian IBD Population: Further Support for Significant Disease Heterogeneity. *American Journal of Gastroenterology* 103(10)2519-2526.  
Journal Impact Factor: 9.21 Citations: 73
56. **Doecke JD**, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC, Hayward NK, Webb PM, Whiteman DC. (2008). Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. *International Journal of Cancer* 123(1)174-180.  
Journal Impact Factor: 5.01 Citations: 78
57. Simms LA, **Doecke JD**, Walsh MD, Huang N, Fowler EV, and Radford-Smith GL. (2008). Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. *GUT* 57(7):903.  
Journal Impact Factor: 13.32 Citations: 194
58. Hourigan MJ, **Doecke JD**, Mollee PN, Gill DS, Norris D, Johnson DW, Gandhi MK. (2008). A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. *British Journal Of Haematology* 141(6)904-907.  
Journal Impact Factor: 4.96 Citations: 19
59. Hume GE, Fowler EV, **Doecke JD**, Simms LA, Huang N, Palmieri O, Griffiths LR, Florin THJ, Annese V, Radford-Smith GL. (2008). Novel NOD2 haplotype strengthens the association between TLR4 Asp299Gly and Crohn's disease in an Australian population. *Inflammatory Bowel Diseases* 14(5)585-590.  
Journal Impact Factor: 5.48 Citations: 43
60. **Doecke JD**, Zhao ZZ, Stark MS, Green AC, Hayward NK, Montgomery GW, Webb PM, Whiteman DC. (2008). Single nucleotide polymorphisms in obesity-related genes and the risk of esophageal cancers. *Cancer Epidemiology Biomarkers and Prevention* 17(4)1007-1012.  
Journal Impact Factor: 4.32 Citations: 28
61. **Doecke JD**, Day CJ, Stephens ASJ, Carter SL, van Daal A, Kotowicz MA, Nicholson GC, Morrison NA. (2006). Association of functionally different RUNX2 P2 promoter alleles with BMD. *Journal of Bone and Mineral Research* 21(2)265-273.  
Journal Impact Factor: 6.59 Citations: 54
62. Beck BR, **Doecke JD**. (2005). Seasonal bone mass of college and senior female field hockey players. *Journal of Sports Medicine and Physical Fitness* 45(3)347-354.  
Journal Impact Factor: 0.76 Citations: 8



## Referees

### **Dr Graham Radford-Smith**

Gastroenterologist /Senior Researcher  
Royal Brisbane and Women's Hospital  
Queensland Institute of Medical Research  
Ph: (617) 3362 0499  
E-mail: Graham.Radford-Smith@qimr.edu.au

### **Prof Kim-Anh Do**

Department Chair  
Department of Biostatistics,  
The University of Texas MD Anderson Cancer Center,  
Houston, TX  
Ph: (713) 794 4155  
E-mail: kim@mdanderson.org

### **Prof Louise Ryan**

Distinguished Professor  
School of Mathematical Sciences  
University of Technology Sydney  
Ph: (612) 9514 2275  
E-mail: Louise.M.Ryan@uts.edu.au

### **Assoc. Prof Simon Laws**

Genomic Leader/Deputy CSO (CRC-MH)  
School of Medical Sciences  
Edith Cowan University  
Ph: (618) 6304 5128  
E-mail: s.laws@ecu.edu.au